Alzheimer's Disease

VeraBIND™ Tau is a new noninvasive test that offers 96 percent sensitivity and 90 percent specificity, empowering earlier and more accessible Alzheimer's detection

Better diagnostics for neurodegenerative diseases can improve clinical trials to help move groundbreaking therapies to approval

Trailblazing labs are among the first to adopt new tests and treatments for longstanding challenges

Mount Sinai Health System among the first in the world to use blood tests as an early detection tool for Alzheimer’s disease and related dementias in patients

The study compared the accuracy of leading commercial blood tests in detecting amyloid plaques, a characteristic feature of Alzheimer’s

New findings suggest that having two copies of a specific gene could represent a new genetic form of Alzheimer's disease

Integrated single-cell approach to cellular genetic screening uncovers mechanisms driving cancer and autoimmunity

Identifying and quantifying cryptic protein aggregates may help diagnose and develop therapies for brain disorders

Blood NfL levels can provide insights into neurological conditions such as Alzheimer’s, Parkison’s, and Huntington’s diseases

The new test employs a two-step workflow to accurately identify or exclude brain amyloidosis in patients with MCI